Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study

European Journal of Endocrinology

Volumn 156, Issue 1, 2007, Pages 75-82

  Schreiber, I ^a   Buchfelder, M ^b   Droste, M ^c   Forssmann, K ^a   Mann, K ^d   Saller, B ^a,d   Strasburger, Christian J ^e  

^a PFIZER INC   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Endokrinologische Praxis   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTIDIABETIC AGENT; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; INSULIN; OCTREOTIDE; PEGVISOMANT; QUINAGOLIDE; SOMATOMEDIN C RECEPTOR; DRUG DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ACROMEGALY; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FOLLOW UP; GALLSTONE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPOPHYSIS TUMOR; INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE ENDOCRINE NEOPLASIA; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; SIDE EFFECT; SWELLING; TUMOR VOLUME; AGED; DRUG ANTAGONISM; GERMANY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ACROMEGALY; ADULT; AGED; FEMALE; GERMANY; GLUCOSE; HEMOGLOBIN A, GLYCOSYLATED; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; QUESTIONNAIRES; RECEPTORS, SOMATOTROPIN;

EID: 33847700931     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02312     Document Type: Article

References (14)

1. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA & Giustina A. Consensus statement: medical management of acromegaly, European Journal of Endocrinology 2005 153 737-740.
2. Vance ML & Laws ER, Jr. Role of medical therapy in the management of acromegaly. Neurosurgery 2005 56 877-885 (Discussion 877-885).
3. Kopchick JJ, Parkinson C, Stevens EC & Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocrine Reviews 2002 23 623-646.
4. Muller AF, Kopchick JJ, Flyvbjerg A & van der Lely AJ. Clinical review 166: growth hormone receptor antagonists. Journal of Clinical Endocrinology and Metabolism 2004 89 1503-1511.
5. Biermasz NR, Romijn JA, Pereira AM & Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opinion in Pharmacotherapy 2005 6 2393-2405.
6. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou. S, Kleinberg DL, Cook DM, Phillips IS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF & Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
7. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU. Stewart PM. Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
8. Barkan AL, Burman P. Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ & Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Journal of Clinical Endocrinology and Metabolism 2005 90 5684-5691.
9. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ & Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. Journal of Clinical Endocrinology and Metabolism 2003 88 4759-4767.
10. Brabant G, Von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R & Kann P. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Hormone Research 2003 60 53-60.
11. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H & Strasburger CJ. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology 2006 154 213-220.
12. Rose DR & Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Hormone and IGF Research 2002 12 418-424.
13. Drake WM, Bowles SV, Roberts ME, Fode FK, Besser GM, Monson JP & Trainer PJ. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. European Journal of Endocrinology 2003 149 521-527.
14. Besser GM, Burman P & Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187-193.